Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX

Monaco Asset Management SAM acquired a new stake in shares of Nkarta, Inc. (NASDAQ:NKTX) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 2,373,400 shares of the company’s stock, valued at approximately $6,717,000. Nkarta makes up about 0.5% of Monaco Asset Management SAM’s portfolio, making the stock its 13th biggest position. Monaco Asset Management SAM owned approximately 3.32% of Nkarta at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. GSK plc purchased a new position in shares of Nkarta in the 4th quarter valued at approximately $5,829,000. Jane Street Group LLC boosted its position in shares of Nkarta by 118.7% during the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock valued at $247,000 after purchasing an additional 852,559 shares in the last quarter. Millennium Management LLC purchased a new stake in Nkarta in the third quarter worth $1,549,000. Renaissance Technologies LLC grew its stake in Nkarta by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,702,022 shares of the company’s stock worth $3,149,000 after purchasing an additional 556,945 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Nkarta by 300.5% in the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock worth $1,237,000 after purchasing an additional 504,272 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Stock Performance

NASDAQ:NKTX opened at $2.33 on Monday. Nkarta, Inc. has a 12 month low of $1.70 and a 12 month high of $3.72. The company has a market cap of $166.87 million, a PE ratio of -1.48 and a beta of 0.93. The company has a 50 day simple moving average of $2.64 and a two-hundred day simple moving average of $2.58.

Nkarta (NASDAQ:NKTX) last posted its earnings results on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.18). Research analysts forecast that Nkarta, Inc. will post -1.54 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. HC Wainwright lowered their price objective on Nkarta to $14.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Stifel Nicolaus decreased their price target on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research report on Wednesday, June 24th. Evercore set a $9.00 price objective on shares of Nkarta in a research note on Monday, May 18th. Finally, Wall Street Zen cut shares of Nkarta from a “sell” rating to a “strong sell” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Nkarta has a consensus rating of “Moderate Buy” and an average price target of $11.20.

Key Headlines Impacting Nkarta

Here are the key news stories impacting Nkarta this week:

• Positive Sentiment: Stifel maintains a bullish view: Stifel Nicolaus lowered its price target from $11 to $10 but initiated or reaffirmed a “Buy” rating. The revised target still implies approximately 329% upside from the referenced $2.33 share price, providing a positive catalyst for Nkarta (NKTX). Ticker Report article
• Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: The firm reduced its EPS forecasts for the third and fourth quarters of 2026 to losses of $0.46 and $0.48, respectively, and lowered its full-year estimates to losses of $1.86 in 2026, $2.26 in 2027, $1.76 in 2028, $1.53 in 2029 and $1.23 in 2030. These revisions indicate expectations for deeper or more persistent losses, which may pressure NKTX despite HC Wainwright retaining its “Buy” rating and $14 price target. MarketBeat analyst estimates article

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.